Bone marrow stromal cells as 'universal donor cells' for myocardial regeneration therapy

Artificial Cells, Cell Engineering and Therapy

Volumn , Issue , 2007, Pages 333-348

  Luo, J ^a   Chiu, R C J ^a   Shum Tim, D ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70649107483     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781845693077.4.333     Document Type: Chapter

References (86)

1. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004, 292(3):344-350.
2. O'connor C.M., Joynt K.E. Depression: are we ignoring an important comorbidity in heart failure?. J Am Coll Cardiol 2004, 43(9):1550-1552.
3. Hobbs F.D., Kenkre J.E., Roalfe A.K., et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002, 23(23):1867-1876.
4. Hellermann J.P., Jacobsen S.J., Gersh B.J., et al. Heart failure after myocardial infarction: a review. Am J Med 2002, 113(4):324-330.
5. Gehi A.K., Pinney S.P., Gass A. Recent diagnostic and therapeutic innovations in heart failure management. Mt Sinai J Med 2005, 72(3):176-184.
6. Salvador D.R., Rey N.R., Ramos G.C., Punzalan F.E. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2004, (1):CD003178.
7. Wang L., Song S. Digoxin may reduce the mortality rates in patients with congestive heart failure. Med Hypotheses 2005, 64(1):124-126.
8. Nieminen M.S., Kupari M. The hemodynamics effects of ACE inhibitors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1990, 15(Suppl 2):S36-40.
9. Sica D.A. Pharmacotherapy in congestive heart failure: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in congestive heart failure: do they differ in their renal effects in man?. Congest Heart Fail 2001, 7(3):156-161.
10. Auer J.W., Berent R., Eber B. Angiotensin II type 1 receptor blockers and congestive heart failure. Circulation 2001, 104(15):E82.
11. Miller A.B. Is there a role for calcium channel blockers in congestive heart failure?. Curr Cardiol Rep 2001, 3(2):114-118.
12. Francis G.S. Calcium channel blockers and congestive heart failure. Circulation 1991, 83(1):336-338.
13. Meng F., Yoshikawa T., Baba A., et al. Beta-blockers are effective in congestive heart failure patients with atrial fibrillation. J Card Fail 2003, 9(5):398-403.
14. Barry W.H., Gilbert E.M. How do beta-blockers improve ventricular function in patients with congestive heart failure?. Circulation 2003, 107(19):2395-2397.
15. Van Zwieten P.A. The rationale for the use of α-blockers in the treatment of congestive heart failure. Am J Geriatr Cardiol 1992, 1(3):57-61.
16. Frazier O.H., Rose E.A., Oz M.C., et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001, 122(6):1186-1195.
17. Stevenson L.W., Miller L.W., Desvigne-Nickens P., et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004, 110(8):975-981.
18. Hosenpud J.D., Bennett L.E., Keck B.M., et al. The Registry of the International Society for Heart and Lung Transplantation: fourteenth official report - 1997. J Heart Lung Transplant 1997, 16(7):691-712.
19. Schmoeckel M., Nollert G., Shahmohammadi M., et al. Transgenic human decay accelerating factor makes normal pigs function as a concordant species. J Heart Lung Transplant 1997, 16(7):758-764.
20. Diamond L.E., Mccurry K.R., Martin M.J., et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996, 61(8):1241-1249.
21. Zak R. Development and proliferative capacity of cardiac muscle cells. Circ Res 1974, 35(2):17-26. suppl II.
22. Messina E., De Angelis L., Frati G., et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004, 95(9):911-921.
23. Beltrami A.P., Urbanek K., Kajstura J., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001, 344(23):1750-1757.
24. Oh H., Chi X., Bradfute S.B., et al. Cardiac muscle plasticity in adult and embryo by heart-derived progenitor cells. Ann NY Acad Sci 2004, 1015:182-189.
25. Beltrami A.P., Barlucchi L., Torella D., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114(6):763-776.
26. Deb A., Wang S., Skelding K.A., et al. Bone marrow-derived cardiomyocytes are present in adult human heart: a study of gender-mismatched bone marrow transplantation patients. Circulation 2003, 107(9):1247-1249.
27. Roufosse C.A., Direkze N.C., Otto W.R., Wright N.A. Circulating mesenchymal stem cells. Int J Biochem Cell Biol 2004, 36(4):585-597.
28. Quaini F., Urbanek K., Beltrami A.P., et al. Chimerism of the transplanted heart. N Engl J Med 2002, 346(1):5-15.
29. Abbott J.D., Huang Y., Liu D., et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004, 110(21):3300-3305.
30. Kim Y.H. Intramyocardial transplantation of circulating CD34+ cells: source of stem cells for myocardial regeneration. J Korean Med Sci 2003, 18(6):797-803.
31. Beckman R.J., Salzman G.C., Stewart C.C. Classification and regression trees for bone marrow immunophenotyping. Cytometry 1995, 20(3):210-217.
32. Petite H., Viateau V., Bensaid W., et al. Tissue-engineered bone regeneration. Nat Biotechnol 2000, 18(9):959-963.
33. Krause D.S. Plasticity of marrow-derived stem cells. Gene Ther 2002, 9(11):754-758.
34. Ferrari G., Cusella-De Angelis G., Coletta M., et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998, 279(5356):1528-1530.
35. Chiu R.C. Bone-marrow stem cells as a source for cell therapy. Heart Fail Rev 2003, 8(3):247-251.
36. Wollert K.C., Meyer G.P., Lotz J., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364(9429):141-148.
37. Kehat I., Kenyagin-Karsenti D., Snir M., et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001, 108(3):407-414.
38. Kehat I., Khimovich L., Caspi O., et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004, 22(10):1282-1289.
39. Soonpaa M.H., Koh G.Y., Klug M.G., Field L.J. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 1994, 264(5155):98-101.
40. Li R.K., Jia Z.Q., Weisel R.D., et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996, 62(3):654-660. discussion 660-61.
41. Koh G.Y., Klug M.G., Soonpaa M.H., Field L.J. Differentiation and long-term survival of C2C12 myoblast grafts in heart. J Clin Invest 1993, 92(3):1548-1554.
42. Chiu R.C., Zibaitis A., Kao R.L. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg 1995, 60(1):12-18.
43. Atkins B.Z., Lewis C.W., Kraus W.E., et al. Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells. in situ. Ann Thorac Surg 1999, 67(1):124-129.
44. Murry C.E., Wiseman R.W., Schwartz S.M., Hauschka S.D. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 1996, 98(11):2512-2523.
45. Menasche P., Hagege A.A., Scorsin M., et al. Myoblast transplantation for heart failure. Lancet 2001, 357(9252):279-280.
46. Menasche P., Hagege A.A., Vilquin J.T., et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003, 41(7):1078-1083.
47. Wakitani S., Saito T., Caplan A.I. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995, 18(12):1417-1426.
48. Makino S., Fukuda K., Miyoshi S., et al. Cardiomyocytes can be generated from marrow stromal cells. in vitro. J Clin Invest 1999, 103(5):697-705.
49. Tomita S., Li R.K., Weisel R.D., et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999, 100(19 Suppl):II247-II256.
50. Wang J.S., Shum-Tim D., Galipeau J., et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 2000, 120(5):999-1005.
51. Orlic D., Kajstura J., Chimenti S., et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410(6829):701-705.
52. Saito T., Kuang J.Q., Lin C.C., Chiu R.C. Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction. J Thorac Cardiovasc Surg 2003, 126(1):114-123.
53. Stamm C., Westphal B., Kleine H.D., et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003, 361(9351):45-46.
54. Strauer B.E., Brehm M., Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002, 106(15):1913-1918.
55. Assmus B., Schachinger V., Teupe C., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106(24):3009-3017.
56. Wollert K.C., Drexler H. Clinical applications of stem cells for the heart. Circ Res 2005, 96(2):151-163.
57. Patel AN P.R., Brusich D. Minimally invasive cellular therapy for congestive heart failure: a prospective randomized study (Abstract). 41st Annual Meeting of the Society of Thoracic Surgeons 2005, 258.
58. Reffelmann T., Kloner R.A. Cellular cardiomyoplasty - cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure?. Cardiovasc Res 2003, 58(2):358-368.
59. Zhang H., Fazel S., Tian H., et al. Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy. Am J Physiol Heart Circ Physiol 2005, 289(5):H2089-2096.
60. Xiao Y.F., Min J.Y., Morgan J.P. Immunosuppression and xenotransplantation of cells for cardiac repair. Ann Thorac Surg 2004, 77(2):737-744.
61. Gammie J.S., Pham S.M. Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism?. Curr Opin Cardiol 1999, 14(2):126-132.
62. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815-1822.
63. Allers C., Sierralta W.D., Neubauer S., et al. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 2004, 78(4):503-508.
64. Liechty K.W., Mackenzie T.C., Shaaban A.F., et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation afterin utero transplantation in sheep. Nat Med 2000, 6(11):1282-1286.
65. Airey J.A., Almeida-Porada G., Colletti E.J., et al. Human mesenchymal stem cells form Purkinje fibers in fetal sheep heart. Circulation 2004, 109(11):1401-1407.
66. Toma C., Pittenger M.F., Cahill K.S., et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105(1):93-98.
67. Poh K.K., Sperry E., Young R.G., Freyman T., Barringhaus K.G., Thompson C.A. Repeated direct endomyocardial transplantation of allogenic mesenchymal stem cells: safety of a high dose, 'off-the-shelf', cellular cardiomyoplasty strategy. Int J Cardiol 2006, 2.
68. Makkar R.R., Price M.J., Lill M., Frantzen M., Takizawa K., Kleisil T., et al. Intra-myocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction. J Cardiovasc Pharmacol Ther 2005, 10(4):225-233.
69. Saito T., Kuang J.Q., Bittira B., et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002, 74(1):19-24. discussion 24.
70. Macdonald D.J., Luo J., Saito T., et al. Persistence of marrow stromal cells implanted into acutely infarcted myocardium: observations in a xenotransplant model. J Thorac Cardiovasc Surg 2005, 130(4):1114-1121.
71. Zhao R.C., Liao L., Han Q. Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy. J Lab Clin Med 2004, 143(5):284-291.
72. Le Blanc K., Tammik C., Rosendahl K., et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31(10):890-896.
73. Maitra B., Szekely E., Gjini K., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33(6):597-604.
74. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferationin vitro and prolong skin graft survival. in vivo. Exp Hematol 2002, 30(1):42-48.
75. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99(10):3838-3843.
76. Chou S.-H., Kuo T., Liu M., Lee O.K. In utero transplantation of human bone marrow-derived multipotent mesenchymal stem cells in mice. J Orth Res 2006, 24(3):301-312.
77. Najafian N., Khoury S.J. T cell costimulatory pathways: blockade for autoimmunity. Expert Opin Biol Ther 2003, 3(2):227-236.
78. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296(5566):301-305.
79. Matzinger P. An innate sense of danger. Ann NY Acad Sci 2002, 961:341-342.
80. Matzinger P. An innate sense of danger. Semin Immunol 1998, 10(5):399-415.
81. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999, 5(11):1249-1255.
82. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425(6957):516-521.
83. Scheel B., Teufel R., Probst J., et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005, 35(5):1557-1566.
84. Heil F., Hemmi H., Hochrein H., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303(5663):1526-1529.
85. Chiu R.C. Stealth immune tolerance' in stem cell transplantation: potential for 'universal donors' in myocardial regenerative therapy. J Heart Lung Transplant 2005, 24(5):511-516.
86. Wekerle T., Kurtz J., Ito H., et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000, 6(4):464-469.